Primidone improves symptoms in TRPM3 ‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep
Epilepsia · 2023
DOI: 10.1111/epi.17586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Lena-Luise Becker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Primidone, Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Einstein Stiftung Berlin.
Abstract (Originalsprache)
Developmental and epileptic encephalopathy with continuous spike‐and‐wave activation in sleep (CSWS) or DEE‐SWAS is an age‐dependent disease, often accompanied by a decline in cognitive abilities. Early successful treatment of CSWS is associated with a better cognitive outcome. We retrospectively analyzed the clinical, electrophysiological, radiological, and genetic data of children with DEE‐SWAS associated with melastatin‐related transient receptor type 3 gene ( TRPM3 ) missense variants. We report two unrelated children with pharmacoresistant DEE‐SWAS and developmental delay/regression and different heterozygous de novo missense variants in the TRPM3 gene (NM_001366145.2; c.3397 T > C/p.Ser1133Pro, c.2004G > A/p.Val1002Met). The variant p.Val1002Met (previously known as p.Val990Met or p.Val837Met) and p.Ser1133Pro were recently shown to result in a gain‐of‐function effect. Based on this finding, previous drug resistance, and the experimentally demonstrated inhibitory effect of primidone on TRPM3, we initiated an individualized therapy with this drug. In both children, developmental regression was stopped, psychomotor development improved, and CSWS was no longer detectable. To our knowledge, this is the first report of a treatment with primidone in TRPM3 ‐associated CSWS. Our results highlight the importance of early genetic diagnosis in patients with epilepsy and the possibility of precision medicine, which should be considered in the future in individuals with a TRPM3 ‐linked DEE‐SWAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Institute for Cell Biology and Neurobiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium.
- VIB Center for Brain and Disease Research, Leuven, Belgium.
ORCID-Profile: Lena-Luise Becker, Evelien Van Hoeymissen, Thomas Voets, Joris Vriens, Christine Prager, Angela M Kaindl
Förderung
- Deutsche Forschungsgemeinschaft
- Einstein Stiftung Berlin
Zitieren
APA
Becker, L. L., Horn, D., Boschann, F., Van Hoeymissen, E., Voets, T., Vriens, J., Prager, C., & Kaindl, A. M. (2023). Primidone improves symptoms in TRPM3 ‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep. Epilepsia. https://doi.org/10.1111/epi.17586
Vancouver
Becker LL, Horn D, Boschann F, Van Hoeymissen E, Voets T, Vriens J, et al. Primidone improves symptoms in TRPM3 ‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep. Epilepsia. 2023. doi:10.1111/epi.17586
BibTeX
@article{Becker2023,
author = {Becker, Lena-Luise and Horn, Denise and Boschann, Felix and Van Hoeymissen, Evelien and Voets, Thomas and Vriens, Joris and Prager, Christine and Kaindl, Angela M},
title = {Primidone improves symptoms in TRPM3 ‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17586}
}
EUVIMED